Prospects for the use of donor blood components in the treatment of COVID-19 patients

INTRODUCTION. The significance of all components of donor plasma on the process of inflammation in patients with COVID-19 is currently a little-studied problem.
The OBJECTIVE was to determine the effect of components of donor plasma on the inflammatory process in COVID-19.
METHODS AND MATERIALS. The study included 50 patients with coronavirus infection (COVID-19), bilateral polysegmental pneumonia, who received standard therapy. Anticovid plasma transfusions were performed in 38 patients. Quarantine fresh frozen plasma was transfused to 12 patients. Before and after transfusion, changes in biochemical, immune, clinical and instrumental parameters of patients were evaluated in dynamics. Separately, the intensity of humoral immunity to SARS-CoV-2 was evaluated in donors of anticovid plasma and in all patients in dynamics. The dynamics of changes in the parameters of components of donor plasma was studied with an assessment of their correlation relationships between biochemical and immune blood parameters before and after transfusion. The most significant component of donor plasma affecting the inflammatory process in COVID-19 was identified.
RESULTS. After transfusion of any type of donor plasma, the parameter of the intensity of humoral immunity to SARS-CoV-2 increased with normalization of clinical and instrumental parameters and a decrease in the parameters of acute phase inflammatory reactants. The value of the alpha2-macroglobulin index was reduced, and it increased after transfusion. Correlations between acute phase inflammatory reactants and donor plasma components before and after transfusion with any type of donor plasma were consistently studied. As a result, the interrelations of varying degrees of severity with the alpha2-macroglobulin index were revealed.
CONCLUSION. After transfusion of any type of donor plasma, there is an increase in the intensity of humoral immunity to SARS-CoV-2 in the form of the appearance of specific antibodies, the parameters of acute phase inflammatory reactants decrease. One of the significant components of donor plasma affecting the inflammatory process in COVID-19 is alpha2-macroglobulin. The study of the possibility of using alpha2-macroglobulin isolated from donor plasma is one of the promising directions in the complex treatment of COVID-19 patients.

1. Pirogov N. I. Works on experimental and clinical surgery (1832–1840). Collected works in eight volumes. Vol. 1 / eds by A. N. Bakuleva. Moscow, Medgiz, 1957:236. (In Russ.).

2. Lazareva E. Yu., Koloskov A. V. Possibilities of transfusion therapy in surgical practice in patients with cirrhosis of the liver // Grekov’s Bulletin of Surgery. 2019;178(4):76–80. (In Russ.). Doi:10.24884/0042-4625-2019-178-4-76-80.

3. Gazzaruso C., Valenti C., Coppola A., Gallotti P. Impact of convalescent and nonimmune plasma on mortality of patients with COVID-19: a potential role for antithrombin // Clinical Microbiology and Infectious Diseases. 2021;27(4):637–638. Doi:10.1016/j.cmi.2020.09.007.

4. Bratchik A. M. Clinical problems of fibrinolysis. Kiev, Zdorovye, 1993:341.

5. Dorofeykov V.V., Shcherbak I.G., Freidlin T.S., Freidlin I.S. Protein-protein interactions of human alpha-2 macroglobulin and their functional consequences // Scientific Notes of Pavlov University. 2000; 7 (1): 75-77. (In Russ.).

6. Koloskov A. V., Mangushlo A. A. Metalloproteinase ADAMTS 13 // Hematology and transfusiology. 2019;64(4):471–482. (In Russ.). Doi:10.35754/0234-5730-2019-64-4-471-482.

7. Mayansky D. N. New frontiers of hepatology: monograph. Novosibirsk, Nauka, 1992:264. (In Russ.).

8. Temporary guidelines «Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)». Version 13 / approved by the Ministry of Health of the Russian Federation on October 14, 2021. Available at: https://base.garant.ru/74212510/ (accessed: 10.15.2021).

9. Simarova I. B., Kostin A. I., Smirnova Yu. V., Ladygina E. A., Logunov D. Yu., Dolzhikova I. V., Ganchin V. V., Vasin E. A., Baykov A. I., Bulanov A. Yu., Borovkova N. V., Petrikov S. S. Formation of a cohort of anticovid plasma donors with a high titer of antibodies neutralizing the SARS-CoV-2 virus // Hematology and transfusiology. 2020;65(3):242–250. (In Russ.). Doi:10.35754/0234-5730-2020-65-3-242-250.

10. Franchini M., Liumbruno G. M., Piacentini G., Glingani C., Zaffanello M. The Three Pillars of COVID-19 Convalescent Plasma Therapy // Life. 2021;11(4):354. Doi:10.3390/life11040354.

11. Focosi D., Franchini M., Pirofski L. A., Burnouf T., Fairweather D., Joyner M. J., Casadevall A. COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors // Viruses. 2021;13(8):1594. Doi:10.3390/v13081594.

12. Noor R., Tasnim N., Saha C. COVID-19 Pandemic and the Convalescent Plasma Therapy: Possible Benefits and Risks //Current clinical microbiology reports. 2021;(3):1–5. Doi:10.1007/s40588-021-00174-8.

13. Baklaushev V. P., Averyanov A. V., Sotnikova A. G. Preliminary results of the study of the safety and efficacy of plasma convalescents in COVID-19 therapy // Clinical practice. 2020;11(2): 38–50. (In Russ.). Doi:10.17816/clinpract35168.

14. Nazarov P.G. Reactants of the acute phase of inflammation: monograph. SPb., Nauka, 2001: 422. (In Russ.).

15. Federal Law of the Russian Federation No. 125 of 12.07 2012 «On blood donation and its components». Available at: https://base.garant.ru/74212510/ (accessed: 11.23.2020).

16. Order of the Ministry of Health of the Russian Federation (Ministry of Health of Russia) dated April 2, 2013 N 183n «On approval of the rules for the clinical use of donated blood and (or) its components». Available at: https://base.garant.ru/74212510/ (accessed: 11.23.2020).

17. Order of the Ministry of Health of the Russian Federation (Ministry of Health of Russia) dated 25.11.2002 No. 363 «On approval of the instructions for the use of blood components». Available at: https://base.garant.ru/74212510/ (accessed: 11.23.2020).

18. Mayansky D. N. Chronic inflammation: monograph. Moscow, Medicine, 1991:272. (In Russ.).

19. Dorofeykov V. V., Freidlin T. S., Shcherbak I. G. Alpha-2 – macroglobulin as the main cytokine-binding protein of blood plasma // Medical immunology.1999;1(5):5–12. (In Russ.).

20. Matsuda T., Hirano T., Nagasava S., Kishimoto T. Identification of alfa2-makroglobulin as a carrier protein for IL-6 // J. Immunol. 1989; 142(1):148–152.